Neonatal screening or Newborn Screening involves the screening of newborns in the first days of their lives for inborn errors of metabolism and certain disorders that can hinder the normal development of the baby. These disorders, are not apparent at the time of the baby's birth, but have potential to cause permanent neurological, cognitive, tactile and physical damage in the child. Early detection of such diseases enable initiating of suitable interventions to prevent concerning conditions in the long run. Trivitron provides a wide range Newborn Screening instruments, including Modular & Fully Automated NBS Instrumentation, manual & automated equipment and reagent kits. Trivitron's Diagnostic division Labsystems Diagnostics OY occupies the second place in the world when it comes to New Born Screening Technology.
Fluoro Enzymatic Assays
Labsystems Diagnostics' Neonatal Biotinidase kit is for enzymatic determination of biotinidase enzyme activity from blood samples dried on filter paper, with fluorometric detection, intended for newborn screening for biotinidase deficiency. Read More
Labsystems Diagnostics' Neonatal G6PD is an enzymatic method for the quantitative determination of glucose-6-phosphate dehydrogenase activity in blood samples dried on filter paper, with fluorometric detection, intended for newborn screening of glucose-6-phosphate dehydrogenase deficiency. Read More
Labsystems Diagnostics' Neonatal Galactose is a quantitative fluorometric test for the total galactose from dried blood spot samples. The test is based on the combined determination of free and galactose liberated from the cleavage of the galactose-1-phosphate. Read More
Labsystems Diagnostics is the first company in the world to introduce fluorometric microplate based assay for phenylalanine for diagnosing phenylketonuria (PKU) in newborns. Its pioneered Newborn Screening products and systems are based on fluorescence and photometric detections. All the reagent kits can be used manually in modular systems or in fully automated and hands off systems.
Labsystems Diagnostics' Neonatal 17-OH-Progesterone FEIA test is a fluorometric enzyme immunoassay enabling the quantification of 17-hydroxyprogestrone steroid present in blood samples dried on filter paper. The test can be used for the screening of newborn for Congenital Adrenal Hyperplasia (CAH). Read More
Labsystems Diagnostics' Neonatal hTSH FEIA Plus is a fluorometric enzyme immunoassay for the quantitative determination of human thyroid stimulating hormone (hTSH, human thyrotropin) in blood samples dried on filter paper as a primary test for screening of babies for congenital hypothyroidism (CH). Read More
Labsystems Diagnostics' Neonatal IRT FEIA is a fluorometric enzyme immunoassay for the quantitative determination of human immuno reactive trypsinogen (IRT) from blood samples dried on filter paper as a primary test for screening of babies for cystic fibrosis (CF). Read More
Labsystems Diagnostics' Neonatal Toxoplasma gondii IgM FEIA is a fluorometric enzyme immunoassay intended for the determination of IgM-class antibodies to Toxoplasma gondii in blood samples dried on filter paper. The test is intended as a primary method for screening newborns for congenital toxoplasmosis (CT). Read More
To run a successful and cost-effective newborn screening test, there is a requirement for all the instruments and reagents. Trivitron's Labsystems Diagnostics Oy delivers the most sophisticated fully-automated solutions in the highest quality and performance standards, ensuring the highest levels of performance for your lab.
REVOLUTIONARY NS2400 NEONATAL SCREENING AUTOMATE With 25 plate capacity, 10 Assays on board, NS2400 automates the highest throughput sites or can handle the highest workload with extremely flexible, could be customized to your needs Read More
A versatile tool for Newborn Screening with high format flexibility and detection sensibility. Read More
Labsystems Diagnostics introduced world's first fluorometric microplate based assay for screening Phenyl Alanine in newborns to detect Phenylketonuria (PKU) and now on tandem MS along with more than 50 disorders. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) increased the screening possibilities by monitoring levels of amino acids and acylacarnitines. These tests can also be used in screening positive samples as a second tier confirmation test to differentiate between true and false positive samples. LC-MS/MS can detect several disorders with a single injection, which is important in high throughput labs.
2nd tier LC-MS/MS Kit for Congenital Adrenal Hyperplasia.Congenital adrenal hyperplasia (CAH) refers to a group of autosomal recessive disorders that impair cortisol biosynthesis. CAH represents a continuous phenotypic spectrum with over 95% of all cases caused by 21-hydroxylase deficiency. CAH owing to 21-hydroxylase deficiency is the most common cause of genital ambiguity in the newborn and is present in about 1 in 15,000 live births worldwide Read More
NeoMass AAAC is used with Tandem Mass Spectrometry to detect concentrations of amino acid, free carnitine, acylcarnitines, succinylacetone and argininosuccinic acid. Read More
Triviton’s Newborn Screening is based on chemical enzyme assay and monoclonal antibody-based enzyme immunoassay using a microtitre plate, photometry technology has been proved effective in case finding and offers a number of advantages. Reduced labour componentEase of handlingUse of nonradioactive reagentsLong reagent shelf-lifeBetter specificityReduction in potential sample handling and transposition errors These features combine to make this technology appropriate for a large to medium-volume neonatal screening laboratory.Newborn Screening Assays from Dried Blood Spots (DBS)Kits include- NeoScreen TSH, NeoScreen 17OHP, NeoScreen G6PD, NeoScreen Galactose, NeoScreen IRT
Congenital Adrenal Hyperplasia (CAH) includes a group of disorders in which the cortisol production by adrenals is lowered. Cortisol is a steroid hormone necessary to maintenance of blood sugar level, partial maintenance of body fluids and electrolytes and protection of the body against stress. CAH cannot be cured, but it can be effectively treated by steroid substitution therapy if detected in early stage of life and disease course. Because of large individual variation in cortisol secretion, it is also important to monitor treatment very carefully. The means to determine an appropriate replacement dose includes measurement of serum/plasma17-hydroxyprogesterone. Labsystems Diagnostics' Neoscreen 17-OH-Progesterone FEIA test allows quantification of 17-hydroxyprogesterone in dried blood spot samples. Read More
Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is the most common human enzyme deficiency; an estimated 400 million people worldwide are affected by this enzymopathy (6). With regards to the demographics of G6PD deficiency, most of the affected individuals reside in Africa, the Middle East, and Southeast Asia. The G6PD enzyme catalyzes an oxidation/reduction reaction. The G6PD enzyme functions in catalyzing the oxidation of glucose - 6 - phosphateto 6 - phosphogluconolactone while concomitantly reducing nicotinamide adenine dinucleotide phosphate (NADP+ ) to NADPH. This is the first step in the pentose phosphate pathway and is essential for the synthesis of both DNA and RNA (7). G6PD is also responsible for maintaining adequate levels of NADPH inside he cell. Read More
Galactosemia is an inherited metabolic abnormality comprising three distinctive clinical entities of the galactose pathway defects. Classic galactosemia is due to -Dgalactose- 1-phosphate-uridyl-transferase (GALT) defect (1). The test principle is based on extraction of Galactose & Galactose-1-phosphate from dried blood spot followed by enzymatic conversion of Galactose-1-phosphate & Galactose. Two kinds of extraction methods (acidic and heat) can be used for extraction step. After extraction Galactose-1-phosphate converts to Galactose in a reaction catalyst by alkaline phophatase enzyme Then this Galactose & extracted Galactose from dried blood spot converts to Galactonolactone by Galactose Dehydrogenasis & NAD coenzyme. The resulted NADH reduces Tetrazolium salt indicator dye from yellow to pink or red color. The figure demonstrates the reaction cycles. Final color change is used for colorimetric measurement (490 nm ) spectrophotometrically. Read More
Cystic Fibrosis (CF) is an autosomal recessive disorder affecting the lungs, pancreas, intestine and liver. CF is the most common in Caucasians with an incidence rate 1:2500 newborns. CF is caused by mutation in the gene for the protein cystic fibrosis transmembrane conductance regulator (CTFR) [1,2]. Large-scale neonatal screening for CF is performed by indentification of increased levels of immunoreactive trypsinogen (IRT) in blood. Diagnosis of CF is suggested by manifestations of chronic sinopulmonary disease and exocrine pancreatic insufficiency, confirmed by a sweat test. Neoscreen IRT EIA is a solid phase Enzyme immunoassay in which IRT is eluted from dried blood disks. It simultaneously forms a sandwich between the solid phase, coated with an antibody that recognizes Trypsinogen-1 (IRT-1) and excess of conjugate and unbound hIRT is washed away after incubation and the enzymatic reaction with Chromogenic substrate solution ( 3,3',5,5'-Tetramethylbenzidine (TMB) is performed. Read More
Congenital hypothyroidism (CH) is an endocrine disorder of newborns characterized by the decreased levels of thyroid hormones: thyroxine (T4) and triiodothyronine (T3) in periferal blood. In early perinatal period manifestations of CH are often non-specific, subtle or even non-existent [1-2]. However, the disease, if undiagnosed and untreated, leads to severe mental retardation, as well as to growth and developmental disturbances. Read More
A thyroid stimulating hormone (TSH) test is a common blood test used to evaluate how well the thyroid gland is working. For newborns and infants, thyroid hormone is crucial for normal growth and development of the body and brain. TSH Point of birth tests are routinely ordered for newborns across the world as a part of the newborn screening program to enable prompt diagnosis and treatment.